Standard Biotools Inc (LAB)vsStryker Corporation (SYK)
LAB
Standard Biotools Inc
$0.96
+1.27%
HEALTHCARE · Cap: $379.85M
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 29334% more annual revenue ($25.12B vs $85.33M). SYK leads profitability with a 12.9% profit margin vs -87.8%. SYK earns a higher WallStSmart Score of 65/100 (C+).
LAB
Avoid31
out of 100
Grade: F
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LAB.
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -13.1% — below average capital efficiency
Revenue declined 14.2%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LAB
The strongest argument for LAB centers on Price/Book.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : LAB
The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LAB profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
LAB carries more volatility with a beta of 1.37 — expect wider price swings.
SYK is growing revenue faster at 11.4% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 31/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Standard Biotools Inc
HEALTHCARE · MEDICAL DEVICES · USA
Standard Biotools Inc. (LAB) is a leading biotechnology firm committed to advancing the capabilities of genomic analysis and biological research through innovative tools and technologies. The company specializes in high-performance products designed specifically for laboratories focused on genomics and proteomics, significantly improving research accuracy and efficiency. By leveraging proprietary platforms, Standard Biotools empowers scientists to accelerate their discoveries and enhance the quality of their work. With a strategic position within the dynamic biotechnology landscape, LAB is poised to meet the rising demand for sophisticated analytical solutions vital to the life sciences industry.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?